Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C68H106N11O15 |
Molecular Weight | 1317.6339 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN4C(=O)CC([He])C4=O)C(C)C)C=C3)C(C)C
InChI
InChIKey=ERROR
Molecular Formula | C68H106N11O15 |
Molecular Weight | 1317.6339 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Vedotin fragment (Monomethyl auristatin E, MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. MMAE is a potent radiosensitizer. MMAE radiosensitization can be localized to tumors by targeted activatable cell-penetrating peptides.
Approval Year
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29264831
Vedotin fragment (MMAE) was incubated at 1-1000 nM with cultured primary human hepatocytes for 72 h, and CYP1A2, CYP2B6, and CYP3A4 mRNA expression was assessed by quantitative reverse transcription-polymerase chain reaction and CYP-specific probe substrate by liquid chromatography coupled with mass spectrometry, along with microtubule disruption by immunofluorescence staining using anti-β-tubulin antibody and imaging. MMAE up to 10 nM had no significant effect on CYP1A2, CYP2B6, and CYP3A4 mRNA expression and activity, whereas at higher concentrations of 100- and 1000-nM MMAE, the CYP mRNA expression and activity were diminished substantially. At the clinical dose, the concentration of MMAE was 7 nM which did not show any significant CYP suppression or microtubule disruption in hepatocytes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:59:17 GMT 2023
by
admin
on
Sat Dec 16 13:59:17 GMT 2023
|
Record UNII |
Q3606FDE0B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67422
Created by
admin on Sat Dec 16 13:59:19 GMT 2023 , Edited by admin on Sat Dec 16 13:59:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Q3606FDE0B
Created by
admin on Sat Dec 16 13:59:19 GMT 2023 , Edited by admin on Sat Dec 16 13:59:19 GMT 2023
|
PRIMARY | |||
|
C152842
Created by
admin on Sat Dec 16 13:59:19 GMT 2023 , Edited by admin on Sat Dec 16 13:59:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL2364667
Created by
admin on Sat Dec 16 13:59:19 GMT 2023 , Edited by admin on Sat Dec 16 13:59:19 GMT 2023
|
PRIMARY | |||
|
300000044630
Created by
admin on Sat Dec 16 13:59:19 GMT 2023 , Edited by admin on Sat Dec 16 13:59:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE->CONJUGATE COMPONENT | |||
|
PARENT -> DERIVATIVE | |||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE->CONJUGATE COMPONENT | |||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE -> TOXIN | |||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE->CONJUGATE COMPONENT | |||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
MOLECULAR FRAGMENT | |||
|
CONJUGATE -> TOXIN |
|
||
|
CONJUGATED ANTIGEN -> CONJUGATE COMPONENT | |||
|
CONJUGATE -> TOXIN | |||
|
CONJUGATE->CONJUGATE COMPONENT |
|
||
|
CONJUGATE->CONJUGATE COMPONENT |
|